BioHive-2
Biopharma's most powerful supercomputer for processing biological and chemical data
Platform · On PremiseCompany source
Company profile
About Recursion Pharmaceuticals
Recursion uses AI to analyze images of cells and train artificial intelligence to understand the vast unknown biological space driving disease.
Company description Recursion Pharmaceuticals official website
Mission. Decoding biology to radically improve lives.
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Work at Recursion Pharmaceuticals?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Advanced solid tumors
- B-cell malignancies
- Familial adenomatous polyposis
- Hypophosphatasia
- Relapsed or refractory B-cell lymphomas
- Solid tumors and hematology oncology
- Solid tumors and lymphoma
Who it serves
- Biotech partners
- Pharma
Deployment & integration
On Premise · Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
First patient dosed in Phase 1 clinical study of REC-3565 for B-cell lymphomas; Positive Phase 1b/2 results from REC-4881 TUPELO trial; Built BioHive-2 supercomputer with NVIDIA
Partnerships
Recorded partners
- Next-generation data partnerships
- NVIDIA (BioHive-2 supercomputer)
- Pharmaceutical partnerships with industry leaders mentioned but not named
- Technology partnerships with computational titans
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
REC-3565
Selective MALT1 inhibitor for relapsed or refractory B-cell lymphomas in Phase 1
Other · OtherCompany source
REC-4881
Drug candidate for familial adenomatous polyposis showing positive Phase 1b/2 results
Other · OtherCompany source
Recursion Operating System (Recursion OS)
AI platform to industrialize drug discovery from target identification to clinical trial enrollment
Platform · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery Data.Journal of chemical information and modeling · Mar 23, 2026
Boltz-ABFE: Free Energy Perturbation without Crystal Structures.Journal of chemical theory and computation · Feb 24, 2026
Fifteen Years, One Mission: Innovative, Inspirational, and Impactful Discoveries.ACS medicinal chemistry letters · Jan 8, 2026
Practically Significant Method Comparison Protocols for Machine Learning in Small Molecule Drug Discovery.Journal of chemical information and modeling · Sep 22, 2025
Insights on Volume of Distribution of Acids.Journal of medicinal chemistry · Aug 28, 2025
Sustained Accumulation of Molecular Clock Suppressors Period 1 and Period 2 Promotes C2C12 Myotube Atrophy Through an Autocrine-Mediated Mechanism With Relevance to Androgen Deprivation-Induced Limb Muscle Mass Loss.Function (Oxford, England) · Aug 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Speed and efficiency improvements
Demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages
Data generation scale
2.2 million samples processed per week, >50 petabytes of proprietary data, millions of phenomics images per week
Cell production
Over 100 billion cells per year for high throughput experiments, one of largest HUVEC cell producers globally
Internal Pipeline Development
Accelerated drug discovery from hit identification to IND-enabling studies using the Recursion OS platform
Demonstrated significant improvements in speed, efficiency, and reduced costs compared to traditional pharmaceutical company averages
NVIDIA Partnership
Built BioHive-2, biopharma's most powerful supercomputer to process massive biological and chemical datasets for AI drug discovery
Enabled processing of >50 petabytes of proprietary data across phenomics, transcriptomics, proteomics, and ADME
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Recursion Pharmaceuticals
Recent articles published on Recursion Pharmaceuticals's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
AbbVie Bets $710 Million on AI-Designed Drugs as Nvidia-Backed Startup Eyes Public Markets
Iambic Therapeutics secures pharma giant partnership and files for IPO in same-day move that tests whether artificial intelligence can deliver on drug discovery promises.
Drug Discovery & Research · Sep 24, 2026
Pharma's Computational Arms Race Heats Up as Bristol Myers Squibb Builds Supercomputing Drug Discovery Powerhouse
Bristol Myers Squibb partners with Nvidia to deploy what it claims will be the life sciences industry's most powerful AI infrastructure, signaling an escalating battle for computational supremacy in drug development.
Drug Discovery & Research · Jul 20, 2026
Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem
Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.
Drug Discovery & Research · Jun 26, 2026
What Healthcare AI Can Learn From Vertical AI in Construction
The health AI industry's most durable companies will be those that go deepest in a single clinical domain — not the ones that build the most general-purpose platform. The success of vertical AI in adjacent industries offers a clear template.
Opinion & Analysis · May 23, 2026
Recursion Pharmaceuticals Advances Three AI-Discovered Drug Candidates Into Phase 2 Trials
Recursion Pharmaceuticals has announced that three drug candidates identified through its AI-powered drug discovery platform have advanced into Phase 2 clinical trials, marking a significant milestone for the AI-native pharmaceutical development model.
Drug Discovery & Research · May 3, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.